Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity

Yuan Hong, Indumathi Manoharan, Amol Suryawanshi, Arulkumaran Shanmugam, Daniel Swafford, Shamim Ahmad, Raghavan Chinnadurai, Balaji Manicassamy, Yukai He, Andrew L. Mellor, Muthusamy Thangaraju, David H. Munn, Santhakumar Manicassamy

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

ABSTRACT: The tumor microenvironment (TME) contains high levels of the Wnt family of ligands, and aberrant Wnt-signaling occurs in many tumors. Past studies have been directed toward how the Wnt signaling cascade regulates cancer development, progression and metastasis. However, its effects on host antitumor immunity remain unknown. In this report, we show that Wnts in the TME condition dendritic cells (DCs) to a regulatory state and suppress host antitumor immunity. DC-specific deletion of Wnt co-receptors low-density lipoprotein receptor-related protein 5 and 6 (LRP5/6) in mice markedly delayed tumor growth and enhanced host antitumor immunity. Mechanistically, loss of LRP5/6-mediated signaling in DCs resulted in enhanced effector T cell differentiation and decreased regulatory T cell differentiation. This was due to increased production of pro-inflammatory cytokines and decreased production of IL-10, TGF-β1 and retinoic acid (RA). Likewise, pharmacological inhibition of the Wnts' interaction with its cognate co-receptors LRP5/6 and Frizzled (Fzd) receptors had similar effects on tumor growth and effector T cell responses. Moreover, blocking Wnt-signaling in DCs resulted in enhanced capture of tumor-associated antigens and efficient cross-priming of CD8+ T cells. Hence, blocking the Wnt pathway represents a potential therapeutic to overcome tumor-mediated immune suppression and augment antitumor immunity.

Original languageEnglish (US)
JournalOncoImmunology
Volume5
Issue number4
DOIs
StatePublished - Apr 2 2016

Fingerprint

Low Density Lipoprotein Receptor-Related Protein-6
Low Density Lipoprotein Receptor-Related Protein-5
Dendritic Cells
Immunity
Tumor Microenvironment
Neoplasms
T-Lymphocytes
Cell Differentiation
Wnt Receptors
Frizzled Receptors
Cross-Priming
Wnt Signaling Pathway
Neoplasm Antigens
Regulatory T-Lymphocytes
Growth
Tretinoin
Interleukin-10
Pharmacology
Cytokines
Neoplasm Metastasis

Keywords

  • Antitumor immunity
  • Dendritic cells
  • Immune tolerance
  • LRP5
  • LRP6
  • PORCN inhibitor
  • Wnt

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity. / Hong, Yuan; Manoharan, Indumathi; Suryawanshi, Amol; Shanmugam, Arulkumaran; Swafford, Daniel; Ahmad, Shamim; Chinnadurai, Raghavan; Manicassamy, Balaji; He, Yukai; Mellor, Andrew L.; Thangaraju, Muthusamy; Munn, David H.; Manicassamy, Santhakumar.

In: OncoImmunology, Vol. 5, No. 4, 02.04.2016.

Research output: Contribution to journalArticle

Hong, Y, Manoharan, I, Suryawanshi, A, Shanmugam, A, Swafford, D, Ahmad, S, Chinnadurai, R, Manicassamy, B, He, Y, Mellor, AL, Thangaraju, M, Munn, DH & Manicassamy, S 2016, 'Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity', OncoImmunology, vol. 5, no. 4. https://doi.org/10.1080/2162402X.2015.1115941
Hong Y, Manoharan I, Suryawanshi A, Shanmugam A, Swafford D, Ahmad S et al. Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity. OncoImmunology. 2016 Apr 2;5(4). https://doi.org/10.1080/2162402X.2015.1115941
Hong, Yuan ; Manoharan, Indumathi ; Suryawanshi, Amol ; Shanmugam, Arulkumaran ; Swafford, Daniel ; Ahmad, Shamim ; Chinnadurai, Raghavan ; Manicassamy, Balaji ; He, Yukai ; Mellor, Andrew L. ; Thangaraju, Muthusamy ; Munn, David H. ; Manicassamy, Santhakumar. / Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity. In: OncoImmunology. 2016 ; Vol. 5, No. 4.
@article{f7fa5e9a89fa4f48af4e0159c110533a,
title = "Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity",
abstract = "ABSTRACT: The tumor microenvironment (TME) contains high levels of the Wnt family of ligands, and aberrant Wnt-signaling occurs in many tumors. Past studies have been directed toward how the Wnt signaling cascade regulates cancer development, progression and metastasis. However, its effects on host antitumor immunity remain unknown. In this report, we show that Wnts in the TME condition dendritic cells (DCs) to a regulatory state and suppress host antitumor immunity. DC-specific deletion of Wnt co-receptors low-density lipoprotein receptor-related protein 5 and 6 (LRP5/6) in mice markedly delayed tumor growth and enhanced host antitumor immunity. Mechanistically, loss of LRP5/6-mediated signaling in DCs resulted in enhanced effector T cell differentiation and decreased regulatory T cell differentiation. This was due to increased production of pro-inflammatory cytokines and decreased production of IL-10, TGF-β1 and retinoic acid (RA). Likewise, pharmacological inhibition of the Wnts' interaction with its cognate co-receptors LRP5/6 and Frizzled (Fzd) receptors had similar effects on tumor growth and effector T cell responses. Moreover, blocking Wnt-signaling in DCs resulted in enhanced capture of tumor-associated antigens and efficient cross-priming of CD8+ T cells. Hence, blocking the Wnt pathway represents a potential therapeutic to overcome tumor-mediated immune suppression and augment antitumor immunity.",
keywords = "Antitumor immunity, Dendritic cells, Immune tolerance, LRP5, LRP6, PORCN inhibitor, Wnt",
author = "Yuan Hong and Indumathi Manoharan and Amol Suryawanshi and Arulkumaran Shanmugam and Daniel Swafford and Shamim Ahmad and Raghavan Chinnadurai and Balaji Manicassamy and Yukai He and Mellor, {Andrew L.} and Muthusamy Thangaraju and Munn, {David H.} and Santhakumar Manicassamy",
year = "2016",
month = "4",
day = "2",
doi = "10.1080/2162402X.2015.1115941",
language = "English (US)",
volume = "5",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "4",

}

TY - JOUR

T1 - Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity

AU - Hong, Yuan

AU - Manoharan, Indumathi

AU - Suryawanshi, Amol

AU - Shanmugam, Arulkumaran

AU - Swafford, Daniel

AU - Ahmad, Shamim

AU - Chinnadurai, Raghavan

AU - Manicassamy, Balaji

AU - He, Yukai

AU - Mellor, Andrew L.

AU - Thangaraju, Muthusamy

AU - Munn, David H.

AU - Manicassamy, Santhakumar

PY - 2016/4/2

Y1 - 2016/4/2

N2 - ABSTRACT: The tumor microenvironment (TME) contains high levels of the Wnt family of ligands, and aberrant Wnt-signaling occurs in many tumors. Past studies have been directed toward how the Wnt signaling cascade regulates cancer development, progression and metastasis. However, its effects on host antitumor immunity remain unknown. In this report, we show that Wnts in the TME condition dendritic cells (DCs) to a regulatory state and suppress host antitumor immunity. DC-specific deletion of Wnt co-receptors low-density lipoprotein receptor-related protein 5 and 6 (LRP5/6) in mice markedly delayed tumor growth and enhanced host antitumor immunity. Mechanistically, loss of LRP5/6-mediated signaling in DCs resulted in enhanced effector T cell differentiation and decreased regulatory T cell differentiation. This was due to increased production of pro-inflammatory cytokines and decreased production of IL-10, TGF-β1 and retinoic acid (RA). Likewise, pharmacological inhibition of the Wnts' interaction with its cognate co-receptors LRP5/6 and Frizzled (Fzd) receptors had similar effects on tumor growth and effector T cell responses. Moreover, blocking Wnt-signaling in DCs resulted in enhanced capture of tumor-associated antigens and efficient cross-priming of CD8+ T cells. Hence, blocking the Wnt pathway represents a potential therapeutic to overcome tumor-mediated immune suppression and augment antitumor immunity.

AB - ABSTRACT: The tumor microenvironment (TME) contains high levels of the Wnt family of ligands, and aberrant Wnt-signaling occurs in many tumors. Past studies have been directed toward how the Wnt signaling cascade regulates cancer development, progression and metastasis. However, its effects on host antitumor immunity remain unknown. In this report, we show that Wnts in the TME condition dendritic cells (DCs) to a regulatory state and suppress host antitumor immunity. DC-specific deletion of Wnt co-receptors low-density lipoprotein receptor-related protein 5 and 6 (LRP5/6) in mice markedly delayed tumor growth and enhanced host antitumor immunity. Mechanistically, loss of LRP5/6-mediated signaling in DCs resulted in enhanced effector T cell differentiation and decreased regulatory T cell differentiation. This was due to increased production of pro-inflammatory cytokines and decreased production of IL-10, TGF-β1 and retinoic acid (RA). Likewise, pharmacological inhibition of the Wnts' interaction with its cognate co-receptors LRP5/6 and Frizzled (Fzd) receptors had similar effects on tumor growth and effector T cell responses. Moreover, blocking Wnt-signaling in DCs resulted in enhanced capture of tumor-associated antigens and efficient cross-priming of CD8+ T cells. Hence, blocking the Wnt pathway represents a potential therapeutic to overcome tumor-mediated immune suppression and augment antitumor immunity.

KW - Antitumor immunity

KW - Dendritic cells

KW - Immune tolerance

KW - LRP5

KW - LRP6

KW - PORCN inhibitor

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=84962808865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962808865&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1115941

DO - 10.1080/2162402X.2015.1115941

M3 - Article

VL - 5

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 4

ER -